Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein–Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant
- 1 January 2012
- journal article
- Published by Elsevier in Cytotherapy
- Vol. 14 (1) , 7-11
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Optimization Manufacture of Virus- and Tumor-Specific T CellsStem Cells International, 2011
- Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantationBlood, 2009
- Nucleofection of DCs to Generate Multivirus-specific T Cells for Prevention or Treatment of Viral Infections in the Immunocompromised HostMolecular Therapy, 2009
- Cytotoxic T lymphocytes as immune‐therapy in haematological practiceBritish Journal of Haematology, 2008
- Identification of Hexon-Specific CD4 and CD8 T-Cell Epitopes for Vaccine and ImmunotherapyJournal of Virology, 2008
- Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantationBone Marrow Transplantation, 2007
- Cellular Responses to Viral Infection in Humans: Lessons from Epstein-Barr VirusAnnual Review of Immunology, 2007
- Contact-activated Monocytes: Efficient Antigen Presenting Cells for the Stimulation of Antigen-specific T cellsJournal of Immunotherapy, 2007
- Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cellsBlood, 2004
- Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell linesThe Lancet, 2003